An investigation for investors in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals, Inc. was announced.

San Diego, CA -- (SBWire) -- 11/08/2023 --Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Alnylam Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics.

Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $844.28 million in 2021 to over $1.03 billion in 2022 and that its Net loss increased from $852.82 million in 2021 to over $ 1.13 billion in 2022.

On September 13, 2023, Alnylam Pharmaceuticals, Inc announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients. Analysts commenting on the approval noted the FDA was not overly positive and "emphasized the small treatment effects and was seemingly negative on clinical meaningfulness."

Further, on October 9, 2023, Alnylam Pharmaceuticals, Inc. announced that the FDA issued a Complete Response Letter (CRL) as to the Company's "supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis." Alnylam announced that the CRL indicated that "the clinical meaningfulness of patisiran's treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established, and therefore, the sNDA for patisiran could not be approved in its present form." As a result, the Company announced it would no longer pursue an expanded indication for patisiran in the U.S.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) declined from $242.97 per share on December 21, 2022 to as low as $148.10 per share on October 31, 2023.

Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.